OTUD1 stabilizes PTEN to inhibit the PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize ccRCC to TKIs

• Published in: International journal of biological sciences 2022-01, Vol.18 (4), p.1401-1414
• Main Authors: Liu, Wentao, Yan, Bin, Yu, Haixin, Ren, Jiannan, Peng, Mou, Zhu, Liang, Wang, Yinhuai, Jin, Xin, Yi, Lu
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Angiogenesis inhibitors; Antiangiogenics; Antibodies; Biotechnology; Cancer; Cancer therapies; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - pathology; Cell cycle; Cell growth; Cell Line, Tumor; Cell Proliferation - genetics; Chemotherapy; Clear cell-type renal cell carcinoma; Drug therapy; Female; Genes; Humans; Inhibitors; Kidney cancer; Kidney Neoplasms - metabolism; Kinases; Male; Medical prognosis; Metastases; Metastasis; Neoplasm Proteins - metabolism; NF-kappa B - metabolism; NF-κB protein; Phosphatidylinositol 3-Kinases - metabolism; Plasmids; Protein-tyrosine kinase; Proteins; Proto-Oncogene Proteins c-akt - metabolism; PTEN Phosphohydrolase - genetics; PTEN Phosphohydrolase - metabolism; PTEN protein; Research Paper; Signal Transduction - genetics; Software; Solid tumors; Tumor necrosis factor; Tumor Necrosis Factor-alpha - pharmacology; Tumorigenesis; Tumors; Tyrosine; Ubiquitin-Specific Proteases - metabolism; Ubiquitin-Specific Proteases - pharmacology
• ISSN: 1449-2288; 1449-2288
• DOI: 10.7150/ijbs.68980

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma and has the highest mortality rate. For metastatic RCC, systemic drug therapy is the most important method in addition to surgical tumor reduction. In recent years, tyrosine kinase inhibitors (TKIs) targeting the angiogenesis have been applied to treat ccRCC and achieved profound therapeutic effects. It has been reported that most patients receiving antiangiogenic therapy will develop resistance within 15 months. The mechanism of resistance to targeted therapy is extremely complex and has not been clarified. Ovarian tumor-associated protease domain-containing proteins (OTUDs) belonging to DUBs play a critical role in the tumorigenesis of solid tumors. However, the specific role of OTUDs in ccRCC is still elusive. Here, we investigated the clinicopathological role of OTUD family members in ccRCC. We demonstrated that OTUD1 was downregulated in renal cancer and involved in the poor prognosis of renal cancer. Then, we showed that OTUD1 inhibits cancer cell growth. Moreover, analysis of OTUD1 RNA-seq data indicated that OTUD1 inhibition triggers the AKT and NF-kappa B pathways in renal cancer cells. Furthermore, OTUD1 interacts with PTEN and regulates its stability. Subsequently, we revealed that downregulation of OTUD1 contributes to the sensitivity of renal cancer cells to TKIs, and this effect was blocked by TNF/NF-kappa B inhibitors and AKT inhibitors. Thus, we identified that the OTUD1-PTEN axis suppresses tumor growth and regulates the resistance of renal cancer to TKIs.